Panacea Biotec Amends UNICEF Vaccine Supply Contract to $25M
Filing Summary
Panacea Biotec Ltd has announced an amendment to its existing contract with UNICEF for the supply of its WHO pre-qualified Pentavalent vaccine, Easyfive-TT. The contract value has increased by $8.93 million, bringing the total to approximately $25 million for the years 2026 and 2027. This amendment includes an additional award of $3.68 million for 2027. The contract covers the supply of vaccines for UNICEF’s international requirements. The timeline for execution is set for calendar years 2026 and 2027, with no related party transactions involved.
Panacea Biotec Ltd has received an amended award from the United Nations International Children’s Emergency Fund (UNICEF) for the supply of its WHO pre-qualified Pentavalent vaccine, Easyfive-TT. This amendment follows a previous letter of award dated October 10, 2022, and pertains to supplies scheduled for the calendar years 2023 to 2027.
The amendment results in an increase in the contract value by $8.93 million, raising the total contract value to approximately $25 million for the years 2026 and 2027. Specifically, the value for 2026 has increased by $2.55 million, from $14.25 million to $16.8 million. For 2027, the value has increased by $2.70 million, from $12.48 million to $15.18 million. Additionally, there is an extra award of $3.68 million for 2027.
The scope of the contract involves the supply of the Pentavalent vaccine, Easyfive-TT, which is a fully liquid vaccine covering Diphtheria, Tetanus, Pertussis, Hepatitis B, and Haemophilus influenzae type b (DTwP-HepB-Hib). The vaccine is intended for UNICEF’s international requirements, with the organization responsible for publishing the supplier’s name, vaccine details, duration of the award, and total award value on its website.
The contract is international in nature, with no domestic entities involved. The execution of the contract is scheduled for the calendar years 2026 and 2027. There are no related party transactions associated with this contract, and the promoter or promoter group of Panacea Biotec does not have any interest in UNICEF.
UNICEF is a global organization focused on providing humanitarian and developmental aid to children worldwide. It frequently collaborates with various suppliers to procure vaccines and other essential supplies to support its mission of improving child health and survival rates.
Panacea Biotec Ltd is a biotechnology company engaged in the research, development, manufacturing, and marketing of pharmaceutical formulations and vaccines. The company focuses on providing innovative healthcare solutions and expanding its global presence through strategic partnerships and collaborations.